Omani experience with the use of factor IX Fc fusion protein.

Journal: BMJ Case Reports
Published:
Abstract

We describe our local experience in the management of haemophilia B patients with factor IX Fc fusion protein. Two children with haemophilia B were managed with the use of a personalised/tailored dosing schedule of factor IX Fc fusion protein. Compared with the standard half-life factor IX, prophylaxis with factor IX Fc fusion protein was cost-effective, with much less injections, better bleeding control, improved tolerability or no inhibitor development.

Authors
Shireen I Alzadjali, asser Wali

Similar Latest Advances